VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

November 24, 2021

Primary Completion Date

November 24, 2025

Study Completion Date

June 24, 2026

Conditions
Peripheral Artery Disease
Interventions
DRUG

Sildenafil

"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."

DRUG

Placebo

"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."

Trial Locations (11)

35033

Guillaume MAHE, Rennes

38000

Groupe Hospitalier Mutualiste de Grenoble, Grenoble

Unknown

Amiens University Hospital, Amiens

Bordeaux University Hospital, Bordeaux

Caen University Hospital, Caen

Cholet Hospital, Cholet

Grenoble University Hospital, Grenoble

Mulhouse Hospital, Mulhouse

Nîmes University Hospital, Nîmes

AP-HP - Hôpital Européen Georges Pompidou, Paris

Hospital Paris Saint-Joseph and Hospital Marie Lannelongue, Paris

All Listed Sponsors
lead

Rennes University Hospital

OTHER